Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression

Table 2 Genotype-dependent amino acid polymorphic sites and reverse transcriptase mutations in treatment-naïve patients

RT position	Drug resistance	Mutations in RT region of four genotypes1				Polymorphism	Ref.
		A	B	C	D
38		T (4.4)4			T (14.0)4	A/T/T/A	[83]
53	LMV		D/T (1.8)4			I/N/S/N	[21]
54	ADV	N (2.2)2				T/T/T/H	[83]
84				I (0.5)2		V	[127]
				I (1.5)2			[21]
85				T (0.6)2		S	[127]
91	LMV		I (20.0)4	L (23.5)2	I (16.7)4	I/L/I/L	[83]
					I (14.3)2		[44]
103		I (100)3			I (1.67)3	V	[40]
122		H (47.0)2			H (6.66)2	F	[40]
					L/V/I(25.0)2		[44]
124		H (2.2)3	H (20.0)3	H (11.8)3		N/N/Y/H	[83]
			H (3.6)3	H (6.6)3			[21]
			D (5.5)3
126		H (6.7)4			R (23.7)4	Y/H/H/H	[83]
					R (17.9)4		[44]
					Y (1.4)4 Q (0.5)4		[83]
128	LMV	N (2.2)2			N (1.4)2 I (1.4)2	T	[83]
			I (1.9)2				[38]
129				L (60.0)2	L (21.4)2	M	[44]
			L (1.9)2	L (26.2)2			[38]
		L (100.0)2		L (9.0)2	L (3.3)2		[40]
134				N (40.5)2		D/N/D/D	[38,54]
				E (23.1)3	E (5.0)3		[21,54]
			I/S (1.8)3	E (5.8)3			[21]
139	LMV		K (3.7)2		K (11.9)2	Q/N/N/N	[38]
					K (2.3)3		[83]
				K (1.5)3			[21]
145			L (3.7)2	L (40.5)2		M	[83]
153	LMV	Q (100)2				W/R/R/R	[40]
191	LMV			V (8.3)2		V/I/I/V	[39]
		I (4.6)2		F (7.7)2			[54]
200	LMV	V (2.2)2				A	[83]
207	LMV		M (6.0)2 L (2.3)2			V	[26]
				I (5.9)2			[83]
				I/L/G (2.1)2			[39]
214	LMV/ADV			A (5.9)2	A (2.3)2	V	[83]
		A (0.5)2 I (0.5)2		I (0.6)2	A (0.8)2 E (0.7)2		[127]
215	ADV			E (7.7)2	H (5.0)2 S (5.0)2	Q	[54]
			H (0.9)2		H (3.0)2 S (4.3)2		[127]
					P (2.8)2 S (4.2)2		[83]
217		L (6.7)4			R (0.9)2	R/L/L/L	[83]
221	ADV			F (40.5)2		Y/Y//F/F	[38]
					Y (5.1)2		[83]
226			H/T (33.3)2	H/T (2.4)2		N	[38]
237					T (6.4)2	P	[127]
238	LMV, ETV	H(1.0)2 W(1.0)2	Q (3.9)2	T (8.7)2	H (2.3)2	N/H/N/N	[127]
			Q (1.82)2	S (2.19)2 T (0.73)2			[21]
				T (3.87)2			[39]
		D (2.2)2 T (2.2)2			D (1.4)2		[83]
245					H (1.4)2	Y	[83]
248	ADV		H (7.4)3	H (4.8)3		N	[38]
256	LMV			G (40.0)2	G (10.7)2	S/S/S/C	[44]
			G (20.0)2		G (3.7)2		[83]
			G (5.45)2				[21]
					G (3.7)2		[26]

A total of 29 reported genotype-dependent amino acid polymorphic sites in the RT region in treatment-naïve patients are shown. The first column contains the RT positions and the second column details the relationship between mutations and drug resistance. Column three to six indicate the prevalence of each mutation as percentages, according genotype. Consensus amino acids are presented in column seven.

¹Incidence (%) of mutations in the RT region;

²Putative mutation;

³Pretreatment mutation;

⁴Novel mutation. ADV: Adefovir dipivoxil; ETV: Entecavir; Ldt: Telbivudine; LMV: Lamivudine; TNF: Tenofovir.